Author

P. Xiang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

L. Wang· 3 shared A. Pustilnik· 2 shared B. A. Heinz· 2 shared D. Foster· 2 shared D. Pellacani· 2 shared D. W. Collins· 2 shared J. Hendle· 2 shared K. Westendorf· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

L. Wang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Single-Cell Transcriptomic Profiling Unveils Critical Metabolic Alterations and Signatures in Progression of Atherosclerosis

L. Ma, Y. Zhao, P. Xiang, Q. Chen, M. Hassan, C. Yu

This study uses single-cell RNA sequencing to identify metabolic changes and gene signatures in atherosclerosis progression, revealing altered metabolic pathways and cell-cell interactions.

bioRxiv · Feb 6, 2024 · PreprintCell Biology

High Density Domain-Focused CRISPR Screens Reveal Novel Epigenetic Regulators of HOX/MEIS Activation in Acute Myeloid Leukemia

K. Barbosa, A. Deshpande, M. E. Perales, P. Xiang, R. Murad, A. Minkina, N. A. Robertson, F. Schischlik, X. Lei, Y. Sun, A. Brown, D. Amend, I. Jeremias, J. G. Doench, K. Humphries, , A. J. Deshpande

The paper identifies SGF29 as a novel chromatin regulator of MEIS1 and AML oncogenes, showing its role in leukemogenesis and potential as a drug target.

bioRxiv · Dec 12, 2022 · PreprintCancer Biology

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

K. Westendorf, S. Zentelis, L. Wang, D. Foster, P. Vaillancourt, M. Wiggin, E. Lovett, R. van der Lee, J. Hendle, A. Pustilnik, J. M. Sauder, L. Kraft, Y. Hwang, R. W. Siegel, J. Chen, , Ramamurt

This paper identifies LY-CoV1404, a potent SARS-CoV-2 neutralizing antibody effective against multiple variants, including Omicron and Delta, due to its conserved epitope and resistance to common mutations.

bioRxiv · Apr 30, 2021Immunology

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

B. E. Jones, P. L. Brown-Augsburger, K. S. Corbett, K. Westendorf, J. Davies, T. P. Cujec, C. M. Wiethoff, J. L. Blackbourne, B. A. Heinz, D. Foster, R. E. Higgs, D. Balasubramaniam, L. Wang, R. Bidshahri, L. Kraft, , M. de Vries

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

bioRxiv · Sep 30, 2020Immunology

Rottlerin ameliorates DSS-induced colitis by improving intestinal barrier function via activation of the Epac-2/Rap-1 signaling pathway.

X. Song, L. Zuo, L. Wang, Z. Zhu, J. Tao, Y. Jiang, X. Wu, Z. Wang, J. Nian, P. Xiang, X. Zhang, H. Zhao, L. Yu, J. Li, J. Hu

This study shows rottlerin reduces DSS-induced colitis in mice by enhancing intestinal barrier function through the Epac-2/Rap-1 signaling pathway.

bioRxiv · Mar 16, 2020 · PreprintCell Biology